Wide Ranks

FOLD

Amicus Therapeutics, Inc.

9.96

Top Statistics
Market Cap 2 B Forward PE 26.28 Revenue Growth 36.70 %
Current Ratio 3.15 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -21.21 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 137.34 Enterprise / Revenue 6.42 Price To Sales Trailing12 Months 6.03
Profitability
Profit Margins -21.21 % Operating Margins 17.53 %
Balance Sheet
Total Cash 249 M Total Cash Per Share 0.8360 Total Debt 444 M
Total Debt To Equity 248.66 Current Ratio 3.15 Book Value Per Share 0.5990
All Measures
Short Ratio 728.00 % Message Board Id finmb_7009878 Fax 609 662 2001
Shares Short Prior Month 21 M Return On Equity -0.6709 City Princeton
Uuid 18ecfd93-9817-3a94-a13a-c6019ef27903 Previous Close 9.87 First Trade Date Epoch Utc 1 B
Book Value 0.5990 Beta 0.6730 Total Debt 444 M
Volume 1 M Price To Book 16.63 Fifty Two Week Low 9.02
Total Cash Per Share 0.8360 Total Revenue 493 M Shares Short Previous Month Date 1 B
Target Median Price 17.50 Max Age 86400 Recommendation Mean 1.46
Sand P52 Week Change 0.3133 Operating Margins 17.53 % Target Mean Price 17.75
Net Income To Common -104688000 Short Percent Of Float 0.0707 Implied Shares Outstanding 298 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 2 M
Average Volume10days 2 M Total Cash 249 M Next Fiscal Year End 1 B
Revenue Per Share 1.63 Held Percent Insiders 0.0074 Ebitda Margins 4.68 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 9.87 Target Low Price 14.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 10.75 Open 9.87 Free Cashflow -10718250
State NJ Dividend Yield 0.00 % Return On Assets 0.0116
Time Zone Short Name EST Trailing Eps -0.3400 Day Low 9.81
Address1 47 Hulfish Street Shares Outstanding 298 M Price Hint 2
Target High Price 21.00 Website https://amicusrx.com 52 Week Change -0.0962
Average Volume 2 M Forward Eps 0.1600 Recommendation Key strong_buy
Compensation As Of Epoch Date 1 B Quick Ratio 220.00 % Is_sp_500 False
Regular Market Day High 10.06 Profit Margins -21.21 % Debt To Equity 248.66
Fifty Two Week High 14.57 Day High 10.06 Shares Short 20 M
Regular Market Open 9.87 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 6.42 Revenue Growth 36.70 % Shares Percent Shares Out 0.0703
Operating Cashflow -26517000 Currency USD Time Zone Full Name America/New_York
Market Cap 2 B Is_nasdaq_100 False Zip 08542
Quote Type EQUITY Industry Biotechnology Long Name Amicus Therapeutics, Inc.
Regular Market Day Low 9.81 Held Percent Institutions 1.05 Current Price 9.96
Enterprise To Ebitda 137.34 Financial Currency USD Current Ratio 3.15
Gross Margins 89.99 % Industry Disp Biotechnology Number Of Analyst Opinions 12
Country United States Float Shares 241 M Two Hundred Day Average 10.92
Enterprise Value 3 B Price To Sales Trailing12 Months 6.03 Forward PE 26.28
Regular Market Volume 1 M Ebitda 23 M Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases.

Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline.

Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.